hrp0086p1-p22 | Adrenal P1 | ESPE2016

An Assessment of the Hypothalamic–Pituitary–Adrenal Axis in Children with Prader–Willi Syndrome

Kyriakou Andreas , Lewis Sarah , Coveney John , Roche Edna F.

Background: In children with Prader–Willi Syndrome (PWS), hypothalamic dysfunction plays a key role in the development of aberrant energy regulation, sleep-related breathing disorders, hypogonadism and impaired linear growth. Dysfunction of the hypothalamic–pituitary–adrenal (HPA) axis may contribute to the high incidence of sudden death. The prevalence and the extent of the dysfunction of HPA axis remain unclear.Method: Thirty-one (10M/21...

hrp0082p2-d1-455 | Growth | ESPE2014

The Effect of Long Term GH Therapy in Discordant Twins Where One Twin is Born Small for Gestational Age: A Case Control Study

Letshwiti Johannes , O'Mullane Elaine , Hoey Hilary , Roche Edna

Background: The positive effect of GH therapy in small for gestational age (SGA) singletons has been shown in previous studies. Little is known about twin growth and GH treatment where only one twin is born SGA.Objective and hypotheses: We present data from two set of twins where one was appropriate for gestational age (control) and the other twin was SGA (treatment).Method: Twin pair 1: male monochorionic diamniotic (MCDA) twins b...

hrp0098p1-252 | Growth and Syndromes 3 | ESPE2024

Growth Hormone Therapy in Prader Willi Syndrome – Audit of Age of Initiation Over Time in a Tertiary Centre

Dolan Ciara , Hardiman Daniel , Stewart Philip , Roche Edna

Background: Prader-Willi Syndrome (PWS), is a rare complex, genetic neurodevelopmental disorder characterised by hypotonia, poor feeding, neonatal failure to thrive. Untreated, patients progress to hyperphagia and life-limiting extreme obesity. Growth hormone therapy (GHt) is currently the only licenced therapy in PWS. The consensus statement by Deal et al, suggested GH treatment at around 2-years before the onset of obesity. While there are no data to support...

hrp0095p1-46 | Diabetes and Insulin | ESPE2022

The incidence of Type 1 diabetes mellitus has stopped falling and is rising again in Ireland – a preliminary report from the Irish Childhood Diabetes National Register

Roche Edna , McKenna Amanda , Ryder Kerry , Fitzgerald Helen , Hoey Hilary , O'Regan Myra

Introduction and Aim: The Incidence of Type 1 diabetes mellitus (T1DM) varies markedly between populations and over time. Recently a number of high incidence countries, including Ireland, have reported a stabilisation and/or reduction in their T1DM incidence rate (IR) in childhood. Ireland, a high incidence country for T1DM, experienced a dramatic increase in T1DM incidence between 1997 and 2008, a stabilisation in incidence between 2014 and 2018 followed by a...

hrp0098p2-90 | Diabetes and Insulin | ESPE2024

Type 1 diabetes incidence in children aged under 15 years living in Ireland during 2022

Roche Edna , McKenna Amanda , Ryder Kerry , Fitzgerald Helen , O'Regan Myra , Hoey Hilary

Aim: The Irish Childhood Diabetes National Register (ICDNR), established in 2008, prospectively collects robust data to monitor the epidemiology of Type 1 diabetes mellitus (T1DM) in children up to the age of 15 years. It is well recognised that the incidence of T1DM in children differs over time and between populations. The recent IDF atlas noted Ireland to have the 10th highest reported T1DM incidence globally. In the Irish population, similar to ...

hrp0089p1-p065 | Diabetes & Insulin P1 | ESPE2018

Evaluation of Diabetes Related Complications and Endothelial Dysfunction in Adolescents with Type 1 Diabetes

Metwally Nehad , Macken Alan , O'Regan Myra , Fitzgerald Helen , McDonnell Ciara , O'Gorman Clodagh S , Molloy Eleanor , Roche Edna F

Introduction: Patients with type 1 diabetes (T1D) are at high risk of developing vascular complications. Endothelial dysfunction is considered the early reversible stage in the development of diabetes related vascular disease. Early detection and management of endothelial dysfunction can delay or even prevent the development of vascular complications.Aim: Endothelial dysfunction is associated with poor metabolic control in adolescents with T1D. Based on ...

hrp0082p1-d3-88 | Diabetes (2) | ESPE2014

Improved Health-related Quality of Life with Insulin Therapy in Children with Cystic Fibrosis-related Diabetes: a Prospective Cohort Study

George Sherly , Hoey Hilary M C V , Costigan Colm , Murphy Nuala , Roche Edna F , O'Riordan Stephen M P

Background: Cystic fibrosis-related diabetes (CFRD) is a common complication in cystic fibrosis (CF). CFRD symptoms and treatment may impose additional burden and adversely affect their QoL.Objective and hypotheses: Assess HRQoL in CF children with normal glycaemia (CFN) and CFRD and evaluate the change in HRQoL over 1 year period along with clinical changes.Method: A prospective study was undertaken including children aged 10&#150...

hrp0082p1-d2-211 | Reproduction (1) | ESPE2014

The Incidence of Childhood Gonadoblastoma Over 15 Years in the Republic of Ireland

O'Connell Susan M , Lynch Sally-Ann , Coyle David , McDermott Michael , O'Sullivan Maureen , Roche Edna , Quinn Feargal , Cody Declan

Background: Gonadoblastoma is a rare tumour of the gonads presenting in childhood or adolescence. It is a lesion composed of a mixture of germ cells at different stages of maturation, with low malignant potential. It is associated with disorders of sex development (DSD), most commonly Turner mosaic syndrome with Y chromosome material (TMSY), and 46XY gonadal dysgenesis (GD). Little is known about the natural history and incidence of this rare tumour.Obje...

hrp0092rfc14.5 | Adrenals and HP Axis | ESPE2019

Bioactive IGF-I Concentration Compared to Total IGF-I Concentration Before and After 1 Year of High-Dose Growth Hormone in Short Children Born Small for Gestational Age - North European SGA Study (NESGAS)

Beck Jensen Rikke , Gersel Wegmann Mathilde , Thankamony Ajay , Roche Edna , Hoey Hilary , Kirk Jeremy , Ivarsson Sten-A. , Söder Olle , Frystyk Jan , Dunger David B. , Juul Anders

Background: Children born small for gestational age (SGA) exhibit wide variations in the activity of growth hormone (GH)/insulin–like growth factor–I (IGF-I) axis and this heterogeneity may result in supra physiological concentrations of IGF-I during GH treatment. The long-term effects of elevated IGF-I levels has been a matter of concern. We explored the variations in total IGF-I and bioactive IGF-I and the associations with growth and glucose metab...

hrp0086p1-p604 | Growth P1 | ESPE2016

The Exon3-Deleted Growth Hormone Receptor Gene Polymorphism (d3-GHR) is Associated with Increased Spontaneous Growth and Impaired Insulin Sensitivity in Prepubertal Short SGA Children (NESGAS)

Wegmann Mathilde Gersel , Jensen Rikke Beck , Thankamony Ajay , Kirk Jeremy , Donaldson Malcolm , Ivarsson Sten-A , Soder Olle , Roche Edna , Hoey Hillary , Dunger David B , Juul Anders

Background: A common polymorphism in the growth hormone receptor gene (d3-GHR) was found to be associated with pre- and postnatal growth and GH-induced growth. D3-GHR was associated with glucose metabolism in adults with GHD and acromegaly, but this has not previously been explored in children.Objective and hypotheses: We examined the impact of the GHR-exon-3 deletion on glucose metabolism and anthropometrics in short SGA children before and following 1 ...